Bharat Biotech’s cholera vaccine successfully completes Phase-III trials

feature-image

Play all audios:

Loading...

Newsletters ePaper Sign in HomeIndiaKarnatakaOpinionWorldBusinessSportsVideoEntertainmentDH SpecialsOperation SindoorNews ShotsExplainersBengaluruTrendingPhotosDH BrandspotHomeNews


ShotsTrendingMenu×ADVERTISEMENT ADVERTISEMENT ADVERTISEMENTHomescienceBharat Biotech’s cholera vaccine successfully completes Phase-III trialsThe vaccine maker, in a press release, said it


has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV.PTILast Updated : 21 May


2025, 09:12 IST Follow Us :


CommentsADVERTISEMENTPublished 21 May 2025, 09:12 ISThealthScience NewsVaccineCholeraFollow us on : Follow Us IndiaSouthNorthWestEast & North EastOperation SindoorOpinionEditorialSpeak


OutCartoonKarnatakaBengaluruSportsCricketIPL 2025FootballEntertainmentMovie ReviewsPhotosTechnologyWorldSpecialsDH on SundayDH on SaturdaySign up for NewslettersAll NewslettersTop News of


the DayPolitical TheatreDH SportsletterExplainersExplained | Trump says Golden Dome system would cost Canada $61 billion: Here's what it will offerExplained | What is behind the political


tension roiling Bangladesh?Explained | What we know about the escape from a New Orleans jailExplained | What to know about Trump officials' latest move against ColumbiaWhat's BrewingIn


Azerbaijan, Pakistan PM Sharif reiterates his willingness to hold talks with IndiaRussia proposes to hold next talks with Ukraine in Istanbul on June 2PM Modi to tour West Bengal, TMC draws


parallel with visit of ‘migratory birds’Pune dowry death: Police custody of expelled NCP leader, son extended till May 31Latest NewsFrom Delhi to Punjab: Kejriwal's political pivot or


post-poll disarray?Remembering Ratan’s lighter sideLoitering munitions: A gamble in the skyHow Shakti scheme is shaping a new sense of selfThe Printers Mysore


LtdPrajavaniSudhaMayuraEpaperClassifiedsContactAboutPrivacy PolicyTermsDisclaimerGrievance Redressal